Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

Karlijn H G Rutten, Reinier A P Raymakers, Bouke P C Hazenberg, Hans L A Nienhuis, Edo Vellenga, Monique C Minnema

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
239 Downloads (Pure)

Abstract

Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalAmyloid
Volume25
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • AL amyloidosis
  • survival
  • prognosis
  • time trend
  • LIGHT-CHAIN AMYLOIDOSIS
  • STEM-CELL TRANSPLANTATION
  • IMPROVED OUTCOMES
  • STAGING SYSTEM
  • MANAGEMENT
  • PROGNOSIS
  • MELPHALAN

Cite this